Email
Print
Nucleic Acid Aptamers Market - Forecast(2023 - 2028)
Nucleic Acid Aptamers Market
Nucleic Acid Aptamers Market Size is estimated to reach $481 million by 2028 and it is poised to grow at a CAGR of 17.3% over the
forecast period of 2023-2028. Aptamers are small single-stranded
oligonucleotides (DNAs or RNAs) with comparatively low molecular weight,
ranging from 5-40 kDa. The following helps in forming a specific
three-dimensional structure. Nucleic acid aptamer groups have more flexibility
and minor complexity and immunogenicity allowing them to attach to interior
non-accessible epitopes that cannot be easily targeted by antibodies. Aptamer
sciences have been applied in various life sciences fields as a new drug, an agent for diagnostic and bio-imaging,
drug-delivery agents, analytical reagents and food & hazard detection
applications. The nucleic acid aptamers market in the U.S. has been majorly driven by
the aptamer companies in the U.S. who are constantly evolving the sphere of
research to curate products and services which serve a wider purpose. Owing to
the following reasons, the industry will grow at a stupendous pace in the
forecast period of 2023-2028.
Nucleic Acid Aptamers Market Report Coverage
The report: “Nucleic Acid Aptamers Market Forecast
(2023-2028)" by IndustryARC, covers an in-depth analysis of the
following segments in the Nucleic Acid Aptamers Market.
Key Takeaways
- Geographically, North America dominated the market in 2021. It is owing to the presence of robust healthcare infrastructure, supported by both public and private funding. However, Europe is expected to offer lucrative growth opportunities over the forecast period of 2023-2028. It is owing to tremendous development in the healthcare structure, with rising professional streams providing support.
- The rising awareness of the advantages of aptamers over antibodies along with technological growth and support from the rising disease spectrum are the recognized drivers for the market. However, a shortage of skilled and trained professionals to handle a highly nuanced stream of research impedes the market.
- A detailed analysis of the strengths, weaknesses, opportunities and threats will be provided in the Nucleic Acid Aptamers Market Report.
Nucleic Acid Aptamers Market- Market Share (%) by region, 2021.
Nucleic Acid Aptamers Market - by Technology
Nucleic Acid Aptamers Market by technology can be further
segmented into SELEX and Others. The SELEX segment held a dominant market share in
2021 and is estimated to be the fastest-growing, with a CAGR of 18.7% over the
forecast period of 2023-2028. SELEX is an acronym for systematic evolution of
ligands by exponential enrichment. The main advantage of this procedure is to
select aptamers, as nucleic acid-based affinity ligands, without any prior
knowledge of the target. One of the modified SELEX procedures is the
Cell-SELEX, which is used to discover specific aptamers against a whole cell.
Furthermore, the oligonucleotide libraries are 40-100 bases long with 1012
to 1016 distinct sequences. Amplification can be facilitated by PCR
and NGS. Lastly, the reduction in the price of sequencing a human genome to
$942 in 2019 has facilitated the adoption.
Nucleic Acid Aptamers Market - by Application
Nucleic Acid Aptamers Market by the application can be
further segmented into Therapeutics Developments, Drug Delivery Agents,
Analytical Reagents, Food Inspection and Hazard Detection, Diagnostic and
Bio-Imaging Agent and Others. Therapeutics Development held a dominant market
share in the year 2021. The therapeutics development segment dominated the
market due to the increasing number of clinical trials evaluating aptamers for
new therapies and collaborations among aptamer companies & prominent
pharmaceutical and biotechnology firms. For example, nucleic acid aptamers
are used as an anti-biofilm agent for pneumonia, which as per WHO kills nearly
740,180 children in 2019. However, a diagnostic and bio-imaging agent is
estimated to be the fastest-growing, with a CAGR of 17.8% over the forecast
period of 2023-2028. It is owing to its aid in diagnosing the rising prevalence
of chronic diseases across the globe.
Nucleic Acid Aptamers Market - by Geography
North America dominated the market in 2021 with a market share of 40%. It is owing to a stupendous medical infrastructure in America, which supersedes the nucleic acid aptamers market research. However, Europe is estimated to be the fastest-growing region over the forecast period of 2023-2028. It is owing to tremendous growth potential and revenue increment capacity in the region. Further, the nucleic acid aptamers market in the U.K. along with Germany will provide a much-needed growth impetus during the projected period. As per European Commission, EU-based companies increased investments in R&D in the health sector by 10.3% in 2021.
Nucleic Acid Aptamers Market Drivers
The Growing Role of Bacterial-Resistant Diseases Amongst Other Diseases Classes has Proliferated Market Growth.
Aptamers, other than recognized forms of therapeutic
treatment, are highly regarded as antimicrobial agents. Further, biofilm-forming bacteria, which result
in chronic infections, have developed increased resistance against antibiotic
treatments and host defense systems, curating a demand for aptamers in
therapeutic applications. Bacterial drug resistance has been on a significant
rise, with approved antibacterial drugs with the new mechanism on a decline. As
per CDC, in 2019 around 2.8 million anti-microbial resistance infections took
place in the U.S., claiming nearly 35,000 lives. Owing to the presence of
anti-biofilm activity, the technology is highly regarded in fatal infections.
Rising Awareness of the Advantages of Aptamers Over Antibodies has Prevailed to Increase Market Use.
Antibodies have presented a strong challenge for
targeting small molecules, however, aptamers have conducted effectivity in
targeting small molecules. Owing to this they can bind to small molecules and
dyes and thus be easily used in conventional diagnostic kits, extending their
use to point-of-care diagnostics. Furthermore, aptamers are successful to bind
with larger molecules as well. Nearly 98% of all the molecules tend to be
proteins, which intrinsically are larger than the rest. Hence, biomarkers and
diagnostic kits utilize the concept of aptamers- thereby leveraging the growth
of the nucleic acid aptamers industry.
Nucleic Acid Aptamers Market Challenges
A Critical Shortage of Skilled and Trained Professionals for the Application of Aptamers Impedes Market Growth.
Owing to the complexity, the development of aptamers is for
various therapeutic and diagnostic purposes. These processes are highly
technical and involve the use of various complex instruments and laboratory
documentation systems. All these factors make aptamer development a tedious
process and thus limit its uptake among researchers. Further, modified forms of SELEX are needed to apply.
As per Forbes 2021, within U.S. and Canada, roughly one medical laboratory
scientist is available per 1000 people, with higher burnout ratios reported in
people owing to COVID-19. As per the American Society of Clinical Pathology,
nearly 85.3% of lab professionals reported burnout while 36.5% complained of
inadequate staffing.
Nucleic Acid Aptamers Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Nucleic Acid Aptamers Industry. The top
10 companies in the Nucleic
Acid Aptamers market are:
- Aptamer Group
- Raptamer Discovery Group
- Soma-Logic
- Aptamer Sciences
- Aptagen
- Maravai Lifesciences
- Kaneka Corporation
- Neo Ventures Biotechnology
- Aptus Biochem
- Base Pair Technologies
Recent Developments
- In September 2022, Cage Bio- A biotech company and TAGCyx Biotechnology Company announced the execution of a license-based agreement for the development of TAGX-0003. TAGX-0003 is a DNA aptamer possessing potent interferon-gamma (IFNg) antagonistic activity developed by TAGCyx. Under this agreement, CAGE Bio will receive an exclusive worldwide license to develop and commercialize the drug, excluding Japan.
- In September 2022, Nutromics raised $14 million as Dexcom signaled to move into wider sensing capabilities. Nutromics is working on a portfolio of aptamer-based sensors capable of measuring a wide range of analytes.
- In June 2022, Waseda University researchers developed RaptGen, a variational autoencoder that efficiently discovers new aptamers not included in the input SELEX dataset. This novel computational model could one day be the standard method for aptamer generation.
Relevant Titles
Report Code- HCR 0289
Report Code- CMR 0256
Report Code- HCR 22428
For more Lifesciences and Healthcare Market reports, please click here